191 results
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals Inc
7 Dec 23
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
8:41am
studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits
424B5
k05m 2gbw3k4jg0k67
2 Oct 23
Prospectus supplement for primary offering
4:52pm
8-K
EX-99.1
sngq1a5oj6pkeyjeo
24 Jul 23
Regulation FD Disclosure
4:04pm
424B5
xalukx
21 Jul 23
Prospectus supplement for primary offering
4:39pm
8-K
EX-99.2
9s0pxz1s sj05vgt
22 May 23
Regulation FD Disclosure
1:05pm
8-K
EX-99.1
equu5fvn6
22 May 23
Regulation FD Disclosure
1:05pm
8-K
EX-99.1
6jbci aru2
10 May 23
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
5:17pm
8-K
EX-10.1
mw6czckcwsiv4
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
DEFA14A
8lt 0p4az7fq
22 Jul 22
Additional proxy soliciting materials
9:31pm
8-K
EX-99.1
8iwf4u5dmj2 iv3
28 Jun 22
Departure of Directors or Certain Officers
9:46am
DEFA14A
aqtynn2u 3ef
24 Jun 22
Additional proxy soliciting materials
4:24pm
DEFA14A
oyczvsflr y9r4
31 May 22
Additional proxy soliciting materials
4:52pm
8-K
EX-99.2
zpybdizwzf8d7 i5gs
27 May 22
Regulation FD Disclosure
8:44am